CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. - Wikidata - awgldk - TriplyDB

CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.

CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.

http://www.wikidata.org/entity/Q33984240

about

Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing Herbal medicines in Brazil: pharmacokinetic profile and potential herb-drug interactions.Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis Progress toward genetic tailoring of heart failure therapy Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9.

P2860

Q33779389-3ADF8ECB-E9F2-4E99-ABBF-02AC2F4E335E Q33867239-25C7D32B-357D-48EF-A6BD-E1F95BC8506D Q36336024-A5E6A524-D74C-47F8-B530-9FF422A3BCC6 Q37762496-F1512752-31C5-4859-9408-575BC90A43BB Q46046369-AD3D5D61-4BD8-49DE-BF61-6E8DBCF41E79

P2860

CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.

http://www.wikidata.org/entity/Q33984240

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

CYP2C9 genotype and pharmacody ...... and secondary kidney diseases.

@ast

CYP2C9 genotype and pharmacody ...... and secondary kidney diseases.

@en

type

label

CYP2C9 genotype and pharmacody ...... and secondary kidney diseases.

@ast

CYP2C9 genotype and pharmacody ...... and secondary kidney diseases.

@en

prefLabel

CYP2C9 genotype and pharmacody ...... and secondary kidney diseases.

@ast

CYP2C9 genotype and pharmacody ...... and secondary kidney diseases.

@en

P1433

Q33984240-0430B21E-AC76-4CB5-BE43-A8B280D3EED5

P1476

Q33984240-90323720-5CF9-4B74-A6E4-CABD1C6A3ADC

P2093

Q33984240-0063F35D-B150-418F-8BE2-1C35E7D13BEF

Q33984240-038E7D85-1211-47B6-B734-4353E84F94C1

Q33984240-123DC139-1399-49E4-865B-3BAC3FD8D5F1

Q33984240-40693FA8-AC71-400B-8438-85A11A1EADD7

Q33984240-48729716-AC19-4CFE-81E5-BE1CCF92D968

Q33984240-C580FBA2-1C8F-4625-8724-DC11A23A012B

Q33984240-CAC858CC-2E03-44E2-B02A-49C1C1F348D9

Q33984240-E64D4B8F-271E-42FD-837A-E8A6AB636BA9

Q33984240-F064BCCE-FB98-460D-B75B-66B2AB786775

Q33984240-F2F9D256-E860-4E2C-ACBD-2803C637F04F

P2860

Q33984240-0AB0E2F2-B8CB-461A-83D6-D722539721E1

Q33984240-237BB976-8CD3-4952-BEE9-EA75191DCD9E

Q33984240-2DCFF1FA-3EE4-4CF4-95FA-F403D22C042C

Q33984240-35F50355-ADE7-4131-9DFC-CA4359402505

Q33984240-459EDEAC-E533-403F-BC4E-EF975DD71740

Q33984240-5807398E-C844-4A4C-AC89-3E1E4D42370E

Q33984240-6E00847B-E394-4C57-8236-D82EF1A96DA7

Q33984240-76A69C10-A3BE-4B69-8E95-27C712DFF507

Q33984240-9E05AB4E-1B75-4C40-9749-9361990F68EA

Q33984240-A1935550-8BCD-4F2F-A20B-21F093890228

P2888

Q33984240-C2C7AD20-C702-4F01-B183-9CF2DDCBC6A3

P304

Q33984240-6AB29806-9C27-447A-8E1F-5BCF689262EB

P31

Q33984240-82978F64-C1B9-4D18-A57D-2EF1483BC2B6

P356

Q33984240-1E4B70CB-7D98-4CD1-94A7-FE01013D2336

P433

Q33984240-23C444CB-097E-4063-8465-D3E448EF2927

P478

Q33984240-286E0DA3-50FD-475C-8764-EF751619BD97

P577

Q33984240-1806F7F8-D49B-4FFF-8114-6247184CC724

P5875

Q33984240-392F9EC5-9B5C-4DDF-9F7E-88236EC7D400

P6179

Q33984240-7482AB18-4523-4C39-A3E5-D83D6EEA0C76

P698

Q33984240-75B87BA8-AC12-4F06-A468-40084BC1F207

P932

Q33984240-81D6B75B-9EEC-45E8-9EAF-E29AF3F27A52

P356

S00228-009-0707-7

P1433

European Journal of Clinical Pharmacology

P1476

CYP2C9 genotype and pharmacody ...... and secondary kidney diseases.

@en

P2093

Corina Candiani

http://www.w3.org/2001/XMLSchema#string

Joyce A Goldstein

http://www.w3.org/2001/XMLSchema#string

Joyce Blaisdell

http://www.w3.org/2001/XMLSchema#string

Kimberly Dornbrook-Lavender

http://www.w3.org/2001/XMLSchema#string

Melanie S Joy

http://www.w3.org/2001/XMLSchema#string

Ronald J Falk

http://www.w3.org/2001/XMLSchema#string

Susan L Hogan

http://www.w3.org/2001/XMLSchema#string

Tammy Boyette

http://www.w3.org/2001/XMLSchema#string

Tandrea Hilliard

http://www.w3.org/2001/XMLSchema#string

Yichun Hu

http://www.w3.org/2001/XMLSchema#string

P2860

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.

ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.

Antihypertensive therapy in the presence of proteinuria.

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.

Role of CYP2C9 polymorphism in losartan oxidation.

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.

The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.

P2888

s00228-009-0707-7

P304

947-953

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-009-0707-7

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26731300

http://www.w3.org/2001/XMLSchema#string

P6179

1016301431

http://www.w3.org/2001/XMLSchema#string

P698

19669737

http://www.w3.org/2001/XMLSchema#string

P932

2901912

http://www.w3.org/2001/XMLSchema#string